Patents by Inventor Gihad Dargazanli

Gihad Dargazanli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8513246
    Abstract: The invention relates to use of compositions in therapeutics containing a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: August 20, 2013
    Assignee: SANOFI
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat, Benoit Marabout, Pierre Roger
  • Publication number: 20120071536
    Abstract: The invention relates to N-[(2-aza-bicyclo[2.2.1]hex-1-yl)-aryl-methyl]-benzamide derivatives of the general formula (I) where: R is a hydrogen atom or a (C1-C6)alkyl group, (C3-C7)-cycloalkyl, optionally substituted by one or more fluorine, (C3-C7)-cycloalkyl, (C2-C4)alkenyl, phenyl, (C1-C6)alkoxy, hydroxy; R1 is phenyl or naphtyl optionally substituted by one or more halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1-C6)alkyl, NR4R5, (C1-C6)alkylthio, (C1-C6)alkyl-SO2, phenyl or heteroaryl; R2 is one or more hydrogen or halogen atoms, halo-(C1-C6)alkyl, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)-cycloalkyl-(C1-C3)alkyl; R3, R4 and R5 are independently a hydrogen atom or a (C1-C6)alkyl group; R6 is a (C1-C6)alkyl group; R3 and R4 as well as R3 and R6 may form, together with the atoms having them, a 5- or 6-member ring; R4 and R5 may form together a ring selected from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, azepine, optionally substituted by a (C1-C6)alkyl group.
    Type: Application
    Filed: February 9, 2010
    Publication date: March 22, 2012
    Applicant: SANOFI
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Abdel-Kader Mafroud
  • Patent number: 8119687
    Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5) cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: February 21, 2012
    Assignee: Sanofi-Aventis
    Inventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
  • Patent number: 7951821
    Abstract: This invention discloses and claims a compound of general formula (I) in which R1 represents either a hydrogen atom, or an optionally substituted alkyl group, or a cycloalkylalkyl group, or an optionally substituted phenylalkyl group, or an alkenyl group, X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, alkyl and alkoxy groups, R2 represents one or more substituents chosen from halogen atoms, optionally substituted alkoxy and optionally substituted amino. The compounds of this invention exhibit therapeutic utility.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: May 31, 2011
    Assignee: sanofi-aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Benoit Marabout, Pierre Roger, Mireille Sevrin
  • Publication number: 20100280076
    Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5) cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Applicant: Sanofi-Aventis
    Inventors: Ahmed ABOUABDELLAH, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
  • Publication number: 20100267766
    Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.
    Type: Application
    Filed: June 30, 2010
    Publication date: October 21, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
  • Publication number: 20100234424
    Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.
    Type: Application
    Filed: May 20, 2010
    Publication date: September 16, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Pascale MAGAT
  • Patent number: 7790753
    Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: September 7, 2010
    Assignee: sanofi-aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Corinne Veronique
  • Patent number: 7777057
    Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: August 17, 2010
    Assignee: Sanofi-Aventis
    Inventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
  • Patent number: 7776880
    Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: August 17, 2010
    Assignee: sanofi-aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
  • Patent number: 7750025
    Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: July 6, 2010
    Assignee: sanofi-aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat
  • Patent number: 7700585
    Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: April 20, 2010
    Assignee: sanofi-aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Nathalie Rakotoarisoa
  • Publication number: 20100022548
    Abstract: The invention relates to use of compositions in therapeutics containing a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein.
    Type: Application
    Filed: October 5, 2009
    Publication date: January 28, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Pascale MAGAT, Benoit MARABOUT, Pierre ROGER
  • Publication number: 20090286868
    Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.
    Type: Application
    Filed: July 28, 2009
    Publication date: November 19, 2009
    Applicant: Sanofi-Aventis
    Inventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
  • Patent number: 7619089
    Abstract: The invention relates to compositions comprising a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein. Also disclosed and claimed in certain of the embodiments herein are the methods of preparation of compound of formula (I) and its use in therapeutics.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: November 17, 2009
    Assignee: Sanofi-Aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat, Benoit Marabout, Pierre Roger
  • Publication number: 20090258899
    Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.
    Type: Application
    Filed: March 19, 2009
    Publication date: October 15, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Florence MEDAISKO, Maria-Carmen RENONES
  • Publication number: 20080070941
    Abstract: The invention relates to compositions comprising a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein. Also disclosed and claimed in certain of the embodiments herein are the methods of preparation of compound of formula (I) and its use in therapeutics.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 20, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Pascale MAGAT, Benoit MARABOUT, Pierre ROGER
  • Patent number: 7335670
    Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: February 26, 2008
    Assignee: Sanofi-Aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
  • Patent number: 7326722
    Abstract: The present invention discloses and claims a compound of general formula (I) wherein A, X and R2 are as described herein. Also disclosed and claimed is application of this compound in a variety of therapeutic applications.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: February 5, 2008
    Assignee: Sanofi-Aventis
    Inventors: Gihad Dargazanli, Geneviève Estenne-Bouhtou, Pascale Magat, Benoît Marabout, Florence Medaisko, Pierre Roger, Mireille Sevrin, Corinne Veronique
  • Patent number: 7288656
    Abstract: The invention relates to a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein. Also disclosed and claimed in certain of the embodiments herein are the methods of preparation of compound of formula (I) and its use in therapeutics.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: October 30, 2007
    Assignee: Sanofi-Aventis
    Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat, Benoit Marabout, Pierre Roger